Eveline S. J. M. de Bont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eveline S. J. M. de Bont has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Uta Flucke
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
9 shared publications - Winette T. A. van der Graaf
Netherlands Cancer Institute, Amsterdam, The Netherlands
9 shared publications Dunja M.W.M Te Loo
8 shared publications- Frank N. van Leeuwen
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
8 shared publications H.W. Bart Schreuder
8 shared publicationsHanneke I. Vos
8 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
All Supplementary Data from Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance
This file contains all supplementary tables and figures. Supplemental Table S1. COG treatment protocols pediatric ALL patients. Supplementary Table S2. This table contains the "Rosetta Stone" for the antibody and protein nomenclature (HUGO, MiMI, GeneCards) together with the RPPA staining details. Supplementary Table S3. Protein membership for the 31 defined protein functional groups. Supplementary Table S4. ALL protein constellation membership for the 114 protein clusters. Supplementary Table S5. T-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S6. B-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S7. This table shows the univariate and multivariate Cox Proportional Hazard Model Supplementary Table S8. Protein cluster membership for the leukemic cell lines. Supplementary Fig. S1. Computational work flow. Supplementary Fig. S2. The co-occurrence probability matrices are shown for the PFG ''FLI1'' and ''Apoptosis Occurring''. Supplementary Fig. S3. Principal component analysis for the year of collection and for the processing time of the leukemic samples. Supplementary Fig. S4. (A) Unsupervised hierarchical clustering and (B) principal component analysis plot for the CD34+ cells (black) and the pediatric ALL patient samples (red). Supplementary Fig. S5. Unsupervised hierarchical clustering and k-means for all proteins and ALL patients. Supplementary Fig. S6. Optimization calculation meta-galaxy pediatric ALL. Supplementary Fig. S7. Meta-galaxy analysis restricted to B-ALL cases. Supplementary Fig. S8. Significantly changed protein targets identified for each signature and each constellation. Supplementary Fig. S9. A minimal set of 30 antibodies that could predict classification of patients into signatures. Supplementary Fig. S10. (A) Unsupervised hierarchical clustering of pediatric ALL patient samples and leukemic cell lines (N=95)
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessAll Supplementary Data from Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance
This file contains all supplementary tables and figures. Supplemental Table S1. COG treatment protocols pediatric ALL patients. Supplementary Table S2. This table contains the "Rosetta Stone" for the antibody and protein nomenclature (HUGO, MiMI, GeneCards) together with the RPPA staining details. Supplementary Table S3. Protein membership for the 31 defined protein functional groups. Supplementary Table S4. ALL protein constellation membership for the 114 protein clusters. Supplementary Table S5. T-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S6. B-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S7. This table shows the univariate and multivariate Cox Proportional Hazard Model Supplementary Table S8. Protein cluster membership for the leukemic cell lines. Supplementary Fig. S1. Computational work flow. Supplementary Fig. S2. The co-occurrence probability matrices are shown for the PFG ''FLI1'' and ''Apoptosis Occurring''. Supplementary Fig. S3. Principal component analysis for the year of collection and for the processing time of the leukemic samples. Supplementary Fig. S4. (A) Unsupervised hierarchical clustering and (B) principal component analysis plot for the CD34+ cells (black) and the pediatric ALL patient samples (red). Supplementary Fig. S5. Unsupervised hierarchical clustering and k-means for all proteins and ALL patients. Supplementary Fig. S6. Optimization calculation meta-galaxy pediatric ALL. Supplementary Fig. S7. Meta-galaxy analysis restricted to B-ALL cases. Supplementary Fig. S8. Significantly changed protein targets identified for each signature and each constellation. Supplementary Fig. S9. A minimal set of 30 antibodies that could predict classification of patients into signatures. Supplementary Fig. S10. (A) Unsupervised hierarchical clustering of pediatric ALL patient samples and leukemic cell lines (N=95)
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 3. Genetic variants associated with 5-year PFS
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 3. Genetic variants associated with 5-year PFS
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 2. Genetic variants associated with histologic response
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment
Supplementary Table 2. Genetic variants associated with histologic response